A study published in Rheumatology & Autoimmunity challenges the assumption that achieving clinical remission in rheumatoid arthritis is sufficient, showing that patient-reported outcomes vary significantly by drug class even ...
Apr 22, 2026
0
2
Keratin is the fibrous, waterproof protein that builds everything from our hair and nails to a rhino's horn. However, a tiny glitch in it can have problematic outcomes. A new study has found that changes in a keratin gene ...
Two recent studies from the University of California, Riverside, published in the same issue of Gut Microbes highlight the role of a gene called PTPN2 in protecting the gut from harmful bacteria linked to inflammatory bowel ...
Jan 24, 2026
0
384
Patients with rheumatoid arthritis increased their leg muscle volume when treated with an anti-rheumatic drug, offering new hope for improved muscle health.
Oct 16, 2025
0
68
The U.S. Food and Drug Administration has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD).
Sep 29, 2025
0
11
In 2023, the groundbreaking Australian BANDIT (Baricitinib in New Onset Type 1 Diabetes) trial reported that a daily pill of baricitinib, commonly prescribed for rheumatoid arthritis and alopecia, could safely preserve the ...
Sep 18, 2025
0
18
A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, a rare but life-threatening ...
Jul 8, 2025
0
32
A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of Medicine at the University ...
Jun 25, 2025
0
16
Acute myocarditis—sudden inflammation of the heart—causes mild symptoms in most cases, but about 10% of acute myocarditis cases can be sudden and severe, leading to cardiac arrhythmias, heart pump failure, or even death. ...
Jun 23, 2025
0
33
Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an elevated risk of cancer with tofacitinib, compared to TNF inhibitors (TNFi).
Jun 12, 2025
0
17
